Skip to main content

Age-Related Hearing Loss

1
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Autifony Therapeutics
Autifony TherapeuticsUK - Stevenage
1 program
1
AUT00063Phase 23 trials
Active Trials
NCT02832128Completed15Est. Apr 2017
NCT02345031Completed78Est. Jun 2016
NCT02315508Completed91Est. Dec 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Autifony TherapeuticsAUT00063
Autifony TherapeuticsAUT00063
Autifony TherapeuticsAUT00063

Clinical Trials (3)

Total enrollment: 184 patients across 3 trials

NCT02832128Autifony TherapeuticsAUT00063

Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)

Start: May 2016Est. completion: Apr 201715 patients
Phase 2Completed
NCT02345031Autifony TherapeuticsAUT00063

Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss

Start: Jan 2015Est. completion: Jun 201678 patients
Phase 2Completed
NCT02315508Autifony TherapeuticsAUT00063

Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo

Start: Oct 2014Est. completion: Dec 201591 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.